A Comprehensive Investigation: Developing the Pharmaceutical Industry through Artificial Intelligence.

Deepak Jain, Phool Chandra, Zeeshan Ali, Nishat Fatma, Hafsa Khan
{"title":"A Comprehensive Investigation: Developing the Pharmaceutical Industry through Artificial Intelligence.","authors":"Deepak Jain, Phool Chandra, Zeeshan Ali, Nishat Fatma, Hafsa Khan","doi":"10.2174/0115701638313233240830132804","DOIUrl":null,"url":null,"abstract":"<p><p>AI's rise has affected many aspects of civilization. Pharmaceutical businesses have been hit hard. This review paper highlights AI's benefits for disease detection, clinical trials, medicine development, and productivity in the pharmaceutical industry. Pharmaceutical companies have built specialized systems to help doctors diagnose and monitor medication remediation. Pharmaceutical businesses are utilizing AI for machine learning to imitate human analytical processes for more accurate and insightful data. AI has many benefits for the pharmaceutical business. Data analysis can address previously insoluble problems due to improved precision. AI boosts productivity, lowers expenses, and enhances tasks. AI insights enhance understanding of user behavior, market performance, and clinical trial success. AI helps identify patients during clinical trials and improves antiviral detection to ensure efficacy, safety, cost-effectiveness, and seamless pharmaceutical procedures. The pharmaceutical industry emphasizes AI in R&D, drug discovery, diagnostics, sickness prevention, epidemic forecasting, remote access, manufacturing, and marketing. Artificial intelligence has transformed medication development and discovery by analyzing vast datasets, discovering complicated patterns, and forecasting efficacy. Pharmaceutical companies like Novartis, AstraZeneca, and Verge Genomics are utilizing AI for drug feature prediction, neurological evaluation, therapy development, pulmonary and hypertension recognition, low-cost medication production, and disease diagnosis.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug discovery technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115701638313233240830132804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

AI's rise has affected many aspects of civilization. Pharmaceutical businesses have been hit hard. This review paper highlights AI's benefits for disease detection, clinical trials, medicine development, and productivity in the pharmaceutical industry. Pharmaceutical companies have built specialized systems to help doctors diagnose and monitor medication remediation. Pharmaceutical businesses are utilizing AI for machine learning to imitate human analytical processes for more accurate and insightful data. AI has many benefits for the pharmaceutical business. Data analysis can address previously insoluble problems due to improved precision. AI boosts productivity, lowers expenses, and enhances tasks. AI insights enhance understanding of user behavior, market performance, and clinical trial success. AI helps identify patients during clinical trials and improves antiviral detection to ensure efficacy, safety, cost-effectiveness, and seamless pharmaceutical procedures. The pharmaceutical industry emphasizes AI in R&D, drug discovery, diagnostics, sickness prevention, epidemic forecasting, remote access, manufacturing, and marketing. Artificial intelligence has transformed medication development and discovery by analyzing vast datasets, discovering complicated patterns, and forecasting efficacy. Pharmaceutical companies like Novartis, AstraZeneca, and Verge Genomics are utilizing AI for drug feature prediction, neurological evaluation, therapy development, pulmonary and hypertension recognition, low-cost medication production, and disease diagnosis.

全面调查:通过人工智能发展制药业。
人工智能的兴起影响了人类文明的许多方面。制药业受到了严重冲击。本评论文章重点介绍了人工智能在疾病检测、临床试验、药品开发和制药业生产率方面的优势。制药公司建立了专门的系统来帮助医生诊断和监控药物治疗。制药企业正在利用人工智能进行机器学习,以模仿人类的分析过程,从而获得更准确、更有洞察力的数据。人工智能对制药业有很多好处。由于提高了精确度,数据分析可以解决以前无法解决的问题。人工智能可提高生产率、降低成本并改进任务。人工智能的洞察力可增强对用户行为、市场表现和临床试验成功的理解。人工智能有助于在临床试验期间识别患者,并改进抗病毒检测,以确保疗效、安全性、成本效益和无缝制药程序。制药业在研发、药物发现、诊断、疾病预防、流行病预测、远程访问、制造和营销方面都重视人工智能。人工智能通过分析庞大的数据集、发现复杂的模式和预测疗效,改变了药物研发和发现。诺华(Novartis)、阿斯利康(AstraZeneca)和Verge Genomics等制药公司正在利用人工智能进行药物特征预测、神经系统评估、疗法开发、肺部和高血压识别、低成本药物生产和疾病诊断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信